43 completed, 9 unknown, 7 recruiting, 7 terminated. 22 Phase 4, 18 Phase 2, 10 Phase 3, 9 Phase 1, 2 Not applicable.
Follow erenumab: new trials by email Literature Review of erenumab trials Research Report on erenumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Proactively Intervening On Early Cranial Nerve Injury As A Delayed Sequela Of Oropharyngeal Cancer: A Randomized Feasibility Clinical Trial For Pro-Habilitation (proNERVE RCT) Prednisone, Ajovy, Manual Therapy - Cranial Nerve Injury, Oropharyngeal Cancer | Phase 1 | Not yet recruiting | M.D. Anderson Cancer Center | 48 | 2027-03-01 | 2026-09-21 |
| Comparing Migraine Preventive Therapies vs. Anti-CGRP Therapies for Tinnitus in Patients With Migraine (COMPACT-PM) Galcanezumab, Erenumab 70 mg, Eptinezumab - Migraine Associated Vertigo, Tinnitus | Phase 4 | Not yet recruiting | Stanford University | 120 | 2026-07-01 | 2026-06-17 |
| Investigator Initiated Trial of Galcanezumab Treatment in Alzheimer's Disease Galcanezumab - Alzheimer Disease | Early Phase 1 | Recruiting | Xuanwu Hospital, Beijing | 10 | 2025-08-01 | 2026-01-07 |
| Migraine Survey in Gulf Region erenumab - Migraine | Terminated | Novartis Pharmaceuticals | 37 | 2024-06-05 | 2025-11-20 | |
| Migraine Medication Effects on Urinary Symptoms Ubrogepant, Rimegepant, Atogepant - Overactive Bladder, Bladder Pain Syndrome | Enrolling by invitation | The Cleveland Clinic | 200 | 2024-04-05 | 2026-10-19 | |
| Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45 Fremanezumab, Placebo - Migraine, Menstrual Migraine | Phase 4 | Completed | Brigham and Women's Hospital | 15 | 2024-03-01 | 2026-08-26 |
| Emgality for Migraine in Breastmilk Galcanezumab - Migraine | Recruiting | University of California, San Francisco | 30 | 2024-02-26 | 2026-08-11 | |
| Screening Trial for Pain Relief in Schwannomatosis (STARFISH) Siltuximab, Erenumab-Aooe, Siltuximab Matching Placebo - Schwannomatosis, Schwannomas | Phase 2 | Recruiting | Massachusetts General Hospital | 40 | 2023-08-31 | 2026-07-24 |
| Monoclonal CGRP Antibodies for Migraine Prevention - a Nationwide Real Life Study Erenumab, Fremanezumab, Galcanezumab - Migraine, Migraine With Aura | Unknown | Austrian Migraine Registry Collaboration | 1500 | 2022-10-01 | 2022-10-20 | |
| A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period on Efficacy and Safety of Fremanezumab in Chinese Adults With Migraine Fremanezumab, Placebo - Migraine | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 365 | 2022-09-30 | 2025-11-26 |
| China HeadAche DIsorders RegiStry Medicine Overuse Headache/New Daily Persistent Headache, Episodic Migraine and Chronic Migraine, Patients with other types of primary headache - Headache Disorders, Primary, Migraine | Recruiting | Beijing Tiantan Hospital | 10000 | 2022-08-29 | 2026-07-10 | |
| Treatment of Acute PTH With a CGRP Receptor mAb in Military Service Members and Civilians With mTBI Erenumab 140 Mg/mL Subcutaneous Solution, Placebo - Posttraumatic Headache, Mild Traumatic Brain Injury | Phase 2 | Recruiting | Henry M. Jackson Foundation for the Advancement of Military Medicine | 404 | 2022-07-19 | 2024-02-22 |
| Erenumab-aooe for the Management of Trigeminal Neuropathic Pain. Erenumab-Aooe, Placebo - Trigeminal Neuropathy | Phase 2 | Terminated | University of Maryland, Baltimore | 5 | 2022-05-31 | 2024-03-22 |
| Erenumab-aooe for Temporomandibular Disorders Management: TMD Cgrp Antibody RElief (TMD CARE) Erenumab-Aooe 70 MG in 1 mL Prefilled Syringe, Placebo - Temporomandibular Disorders | Phase 2 | Terminated | University of Maryland, Baltimore | 5 | 2022-05-26 | 2024-04-02 |
| Real World Effectiveness of Eptinezumab in Participants With Migraine Eptinezumab, Erenumab, Onabotulinumtoxin-A - Migraine | Phase 4 | Terminated | H. Lundbeck A/S | 32 | 2022-03-04 | 2024-05-29 |
| Efficacy of Erenumab in Chronic Cluster Headache Erenumab, Placebo - Cluster Headache, Trigeminal Autonomic Cephalalgias | Phase 2 | Completed | Charite University, Berlin, Germany | 101 | 2021-12-02 | 2024-01-23 |
| Safety and Efficacy of Fremanezumab for Migraine in Adult CADASIL Fremanezumab, Placebo - Cadasil, Migraine | Phase 2 | Withdrawn | Mayo Clinic | 2021-12-01 | 2022-02-28 | |
| Safety and Efficacy of Erenumab-aooe in Patients With Temporomandibular Disorder Erenumab-aooe (EREN) 140 mg s.c. administered every four weeks for a total of five treatments, Placebo (EREN-P) s.c. administered every four weeks for a total of five treatments - Temporomandibular Disorder | Phase 2 | Completed | Indiana University | 30 | 2021-11-15 | 2025-08-19 |
| Study of Intravenous Erenumab in Patients With Status Migrainosus Erenumab - Status Migrainosus | Phase 1 | Withdrawn | Mayo Clinic | 2021-09-07 | 2022-02-22 | |
| Erenumab For Treatment of Hemicrania Continua Erenumab - Hemicrania Continua | Phase 2 | Terminated | Mayo Clinic | 2 | 2021-08-04 | 2023-02-17 |
Showing 20 of 74. Sign in to see all of them.
Migraine Disorders (50) · Headache (17) · Post-Traumatic Headache (4) · Pain (3) · Recurrence (3) · Brain Concussion (2) · Chronic Pain (2) · Headache Disorders, Primary (2) · Headache Disorders, Secondary (2) · Migraine with Aura (2) · Migraine without Aura (2) · Temporomandibular Joint Disorders (2) · Trigeminal Autonomic Cephalalgias (2) · Alzheimer Disease (1) · Angina Pectoris (1)
Amgen (23) · Novartis Pharmaceuticals (9) · Danish Headache Center (6) · Mayo Clinic (5) · Beth Israel Deaconess Medical Center (2) · IRCCS National Neurological Institute "C. Mondino" Foundation (2) · University of California, San Francisco (2) · University of Maryland, Baltimore (2) · Albany Medical College (1) · Allergan (1) · Austrian Migraine Registry Collaboration (1) · Beijing Tiantan Hospital (1) · Brigham and Women's Hospital (1) · Charite University, Berlin, Germany (1) · David True (1)
United States (43) · Denmark (12) · Germany (9) · Poland (9) · Belgium (8) · Czechia (7) · Finland (7) · Italy (7) · United Kingdom (6) · Austria (5) · Canada (5) · Spain (5) · China (4) · Portugal (4) · Sweden (4)
Messoud Ashina, MD (3) · Carolyn A Bernstein, MD (1) · Charles Argoff, MD (1) · Cristina Tassorelli, MD (1) · David L Brody, MD, PhD (1) · David True (1) · Domenick T Zero, DDS, MS (1) · Gregor Broessner, Prof (1) · Harold C Avila, DDS, MS (1) · Howard B Goldman, MD (1)
PMID 34928306, PMID 35978286, PMID 34301173, PMID 37303034, PMID 31852816, PMID 40275185, PMID 30813769, PMID 30963506, PMID 31816249, PMID 32216456, PMID 32493206, PMID 32636324, PMID 32715736, PMID 32746775, PMID 32851644, PMID 33939497, PMID 34171973, PMID 34600468, PMID 34743579, PMID 36115947, PMID 36380284, PMID 36404301, PMID 36517767, PMID 36798353, PMID 36927366, PMID 37098469, PMID 37679723, PMID 37815254, PMID 38299579, PMID 38516817, PMID 38526461, PMID 38630457, PMID 38630960, PMID 38859744, PMID 39322961, PMID 39344988, PMID 40443263, PMID 40526384, PMID 40980937, PMID 41070535, PMID 41091912, PMID 41223010, PMID 41236158, PMID 41603449, PMID 41641373, PMID 41888647, PMID 41902353, PMID 41991782, PMID 42012062, PMID 42310529
2018 (4), 2019 (4), 2014 (2), 2015 (2), 2023 (2)